Jarquin Campos, Araceli; Risch, Lorenz; Baumann, Marc; Purde, Mette-Triin; Neuber, Sebastian; Renz, Harald; Mosimann, Beatrice; Raio, Luigi; Mohaupt, Markus; Surbek, Daniel; Risch, Martin (2019). Shrunken pore syndrome, preeclampsia, and markers of NO metabolism in pregnant women during the first trimester. Scandinavian journal of clinical and laboratory investigation, 79(1-2), pp. 91-98. Taylor & Francis 10.1080/00365513.2019.1568150
Full text not available from this repository.Shrunken pore syndrome (SPS) is a condition that manifests itself as the decreased renal clearance of low-molecular-weight proteins but normal clearance of creatinine. Pregnant women with evidence of SPS during the first trimester have an increased risk of developing preeclampsia (PE). The nitric oxide (NO) metabolism markers arginine and ADMA, especially their ratio (Arg/ADMA), are recognized markers of endothelial dysfunction. The aim of this nested case-control study was to establish first-trimester reference intervals (RI) for markers of NO metabolism and to study these markers in women with evidence of SPS at the end of the first trimester. Seventy-four women were stratified in the first trimester according to evidence of SPS (SPS + or SPS-) and the occurrence of PE during subsequent pregnancy (PE + or PE-), as follows: SPS-/PE-, SPS+/PE-, SPS-/PE+, and SPS+/PE+. RIs were determined according to the CLSI EP28-A3c guidelines. Serum Arg and ADMA levels were analyzed. The Arg and ADMA concentrations did not differ among the four groups. However, women in the SPS+/PE + group had a significantly lower Arg/ADMA ratio than those in the other 3 groups (p = .02). In conclusion, we defined the first-trimester RI of Arg, ADMA and the Arg/ADMA ratio as markers of NO metabolism. Our results suggest that SPS in the first trimester predicts a pathophysiological hallmark of subsequent PE, i.e. lower NO production leading to increased vessel tone. Early identification of women at risk for later PE could lead to adaptive prophylactic interventions, such as supplementation with Arg or an NO-donor drug in order to mitigate the risk of developing PE.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology |
UniBE Contributor: |
Risch, Lorenz, Baumann, Marc, Mosimann, Beatrice, Raio, Luigi, Surbek, Daniel |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0036-5513 |
Publisher: |
Taylor & Francis |
Language: |
English |
Submitter: |
Monika Zehr |
Date Deposited: |
16 Dec 2019 08:52 |
Last Modified: |
05 Dec 2022 15:33 |
Publisher DOI: |
10.1080/00365513.2019.1568150 |
PubMed ID: |
30785340 |
Uncontrolled Keywords: |
Beta-trace protein beta-2-microglobulin creatinine cystatin C glomerular filtration rate nitric oxide preeclampsia reference intervals |
URI: |
https://boris.unibe.ch/id/eprint/136418 |